Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds
JNS: An expert panel on Tuesday recommended Covaxin (COVID-19 vaccine) for phase-2 and phase-3 clinical trial on younger population aged between 2 to 18 years, official sources said. The trial …
Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds Read More